8-K

  1
                      SECURITIES AND EXCHANGE COMMISSION

                           Washington, D.C.  20549



                                   Form 8-K



                                CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                                 June 21, 2000
               -------------------------------------------------
               (Date of Report: Date of earliest event reported)


                         IMMUNOTECHNOLOGY CORPORATION
            ------------------------------------------------------
      (Exact name of registrant as specified in its charter)


         DELAWARE                    0-24641             84-1016435
- ---------------------------- -----------------------  --------------------
(State or other jurisdiction (Commission File Number) (IRS Employer ID No.)
 of incorporation)



                   1661 Lakeview Circle, Ogden, Utah  84403
                ------------------------------------------------
                    (Address of principal executive office)



Registrant's telephone number, including area code: (801) 399-3632
                                                    --------------

                              Not Applicable
     ---------------------------------------------------------------------
        (Former name or former address, if changed since last report)











                    

 2
                              ITEM 5. OTHER EVENTS

1. Issuance of Shares on Conversion of Promissory Note
- ------------------------------------------------------
On June 21, 2000, the Registrant's board of directors approved the issuance of
1,115,673 shares of the Registrant's common stock to David Knudson, the
Secretary/Treasurer of the Registrant, in exchange for the conversion of
$34,864.78 in principle and accrued interest pursuant to the terms of a
Promissory Note between the Registrant and Mr. Knudson. Prior to the
conversion of the Promissory Note, the Company had 4,884,327 shares of its
common stock issued and outstanding. After giving effect to the issuance of
the conversion shares to Mr. Knudson, the Registrant had 6,000,000 shares of
common stock issued and outstanding.  The shares issued to Mr. Knudson
constitute restricted securities issued pursuant to section 4(2) of the
Securities Act of 1933, as amended.

2. Letter of Intent to Acquire Beverly Hills Auctioneers, Inc.
- --------------------------------------------------------------
On May 19, 2000, the Registrant executed a letter of intent to acquire 100% of
the outstanding common stock of Beverly Hills Auctioneers, Inc., Beverly
Hills, California, for newly-issued shares of capital stock of the Registrant.
The terms of the letter of intent and the press release issued by the
Registrant in connection with the proposed transaction have been attached as
exhibits to this report and are incorporated herein by this reference.

(c)  Exhibits.  The following exhibits are included as part of this report:

            SEC
Exhibit     Reference
Number      Number      Title of Document                        Location
- -------     ---------   -----------------                        --------
20.01         20        Press Release re: Letter of Intent       This Filing


20.02         20        Letter of Intent, dated May 19, 2000     This Filing

                            SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunder duly authorized.

                                         IMMUNOTECHNOLOGY CORPORATION

Date: July 5, 2000                       /S/David Knudson, Secretary/Treasurer

EX-20

Exhibit 20.01

Wednesday June 28, 1:59 pm Eastern Time

Company Press Release

SOURCE: Immunotechnology Corporation

Immunotechnology Corporation Announces Letter of Intent
To Acquire Beverly Hills Auctioneers, Inc.

BEVERLY HILLS, June 28 /PRNewswire/ -- Immunotechnology Corporation
"Immunotech"(OTC Bulletin Board: IMNT-news) today announced the signing of a
letter of intent to acquire 100% of the outstanding common stock of Beverly
Hills Auctioneers, Inc. for newly-issued stock in Immunotech.

Beverly Hills Auctioneers, based in Beverly Hills, California ("BHA"),
provides live auction, evaluation, disposition and purchase services to banks,
courts, attorneys, appraisers, estates, pawnbrokers, retail stores and private
parties for a wide range of fine jewelry, gemstones, and timepieces. BHA has
developed a specialized software system that allows it to efficiently put
together a smooth and profitable auction virtually anywhere. BHA's website is
www.bhauctioneers.com.

The proposed transaction calls for a reverse-split of 1 for 3 shares of the
current issued and outstanding shares of Immunotech prior to issuing
12,500,000 post-split shares to the Beverly Hills Auctioneer's shareholders.
On completion of the acquisition there will be approximately 14,500,000 shares
of common stock outstanding and Immunotech will change its name to Beverly
Hills Auctioneers, Inc. The closing of this transaction is subject to the
execution of a definitive agreement which will contain various representations
and warranties of each party and which will be subject to the approval of the
shareholders of each company. Immunotech will call a special meeting of
shareholders to approve the proposed terms of the acquisition as soon as
possible.

EX-20

 1
Exhibit 20.02 -- Letter of Intent

ImmunoTechnology Corporation
1661 Lakeview Circle
Ogden, UT 84403

May 19, 2000

Board of Directors
Beverly Hills Auctioneers, Inc.
9454 Wilshire Boulevard, Suite 202
Beverly Hills, CA 90212


Re:  Letter of Intent to Acquire all Issued and Outstanding Stock of Beverly
Hills Auctioneers, Inc.

Gentlemen:

The Board of Directors of ImmunoTechnology Corporation (hereafter "Immuno"),
hereby proposes to acquire all of the issued and outstanding stock of Beverly
Hills Auctioneers, Inc. (hereafter referred to as "BHA"), a privately held
California corporation, upon the following terms:

1.  Stock Exchange.  Immuno will acquire all  of the issued and outstanding
shares of capital stock of BHA in exchange  for 12,500,000 shares of Immuno
Common Stock, calculated after a 1 for 3 reverse  stock split, pursuant to the
provisions of Section 368(a)(1)(B) of the Internal Revenue Code, in connection
with a tax free reorganization.  The shares will be issued pursuant to Section
4(2) of the Securities Act of 1933, as amended, and under corresponding
applicable state law.  The parties acknowledge that it is their intent,
subject to the provisions hereof, for Immuno to acquire all of the issued and
outstanding stock of BHA.

2.  Management.  At the time of closing, the current officers and directors of
Immuno will resign and the designates of BHA will be appointed as officers and
directors of Immuno.

3.  Definitive Agreement.  This Letter of Intent is a non-binding indication
of the parties proposal to effect an acquisition of BHA by Immuno.  Subject to
the fulfillment of all conditions set forth herein, the parties intend to
enter into a definitive Agreement and Plan of Reorganization setting forth all
applicable  terms of the acquisition with standard representations and
warranties.  Either party hereto may, without incurring obligation or
liability to the other party, terminate this Letter of Intent at any time
prior to the signing of a definitive Agreement and Plan of Reorganization.
Any termination of this Letter of Intent, except by its own terms, must be in
writing and mailed to the other party by first class US mail.

4.  Change of Name.  The name of Immuno will be changed to "Beverly Hills
Auctioneers, Inc.," or such other name as is selected by the parties and
approved by the shareholders of Immuno.

5.  Reverse Stock Split.  Immuno will effect a 1 for 3 reverse stock split in
connection with and prior to the consummation of the acquisition of BHA.

6.  Private Placement.  A private placement of Immuno's securities after the
closing of the acquisition of BHA and after the 1 for 3 reverse stock split
shall be structured as follows:


 2

     A.  Immuno will offer and sell up to 350,000 shares of its common stock
for cash at a price of $2.00 per share, in a private placement.

     B.  In the event a minimum of $600,000 of the private placement funding
is raised within 60 days after the closing of the acquisition of BHA by
Immuno, 8,500,000 of the Immuno shares issued to the BHA stockholders will be
delivered to Immuno's transfer agent for cancellation within 30 days after
completion of the private placement.

7.  Conditions Precedent.  The acquisition of BHA by Immuno proposed herein is
subject to the following conditions:

     A.  The approval of the proposed acquisition and related transactions by
the shareholders of Immuno.  A special meeting of  the shareholders of Immuno
will be called for  as soon as practical to consider the proposed acquisition,
a change of Immuno's name, and the election of directors as designated by BHA.

     B.  The approval of the proposed acquisition and related transactions by
the owners of all issued and outstanding shares of BHA.

     C.  Compliance by Immuno with all applicable federal and state securities
laws, including Rule 14A, Rule 13e-3, Rule 14f-1, and Rule 10b-17 of the
Exchange Act.

     D.  The delivery to Immuno by BHA of financial statements of BHA and its
predecessors for the last two (2) fiscal years and for the three (3) month
period ending March 31, 2000, and such other financial statements of BHA as
are necessary to comply with the requirements of the Securities and Exchange
Commission.

     E.  The delivery of such documents and information as are reasonably
requested by each party.

     F.  The execution of a definitive Agreement and Plan of Reorganization
containing all representations contained herein and other representations and
warranties which are standard in similar transactions.

     G.  Immuno shall have no debts or liabilities as of the date of closing
the acquisition of BHA.

8.  Representations.

     A.  Immuno and BHA will be duly organized and in good standing in their
respective states of organization at the time of closing.

     B.  All certificates evidencing shares of Immuno issued to the
shareholders of BHA will be legended as restricted under rule 144 as
promulgated under the Securities Act of 1933, as amended.

     C.  Each company shall deliver such documents and financial statements to
the other company as is reasonably requested prior to closing of the
transaction subject to execution by the receiving party, if requested by the
delivering party, of a confidentiality agreement.

     D.  All shares of Immuno Common Stock issued in connection with the
proposed acquisition will be fully paid and non-assessable.

     E.  The total number of shares of Immuno to be issued and outstanding
immediately prior to closing will not exceed 2,000,000, taking into effect a 1
for 3 reverse stock split.
 3

9.  Information.  BHA agrees to cooperate in providing and explaining the
following information with respect to the transaction contemplated herein:

     A.  History  and business background  of BHA and any  subsidiary
corporations.  This  shall include a  general discussion of the  business of
the  Company, including plans  for future business, market  for products, and
a brief historical background of the formation or acquisition of the company
and business involved.

     B.  Detailed business biographical information for the last five years
for each of the proposed new members of Immuno management.

     C.  Financial statements of BHA as referred to in Paragraph 7(D) of this
Letter of Intent.

10.  Closing.  Immediately  after the shareholders meeting of  Immuno,
provided that the shareholders of Immuno approve this transaction, a closing
shall be  held with regard to this  transaction.  At the Closing, Immuno shall
deliver minutes of a meeting of the  Board of Directors and  stockholders of
Immuno authorizing and approving the transactions set forth herein along with
appointment of new management and  such other matters as are deemed necessary
to consummate this transaction.  At the closing,  all assets, bank accounts
and other records  and information of Immuno shall be turned over to new
management.

11.  News Releases and Communications.   As soon as practicable, after the
date of  execution hereof, Immuno and BHA may issue a press  release to their
shareholders, the financial community, and  other interested parties
describing this agreement and the proposed transaction.

12.  Conduct of Business.  The parties hereto hereby agree to conduct their
business in accordance with the usual and normal course of business heretofore
conducted by the companies.  Thus, there will be no material adverse changes
in the business of either company from the date hereof until the closing of
this transaction and there will be no changes in either company's Articles of
Incorporation or Bylaws.

13.  Capital Stock.  Immuno hereby represents that it has two classes of
authorized stock which are its $.00001 par value voting Common Stock, of which
50,000,000 shares are  authorized and 6,000,000 are issued and outstanding,
and its $.00001 par value Preferred Stock, of which 5,000,000 shares are
authorized and -0- are issued and outstanding.  Immuno will in connection with
the acquisition proposed herein, effect a 1 for 3 reverse stock split reducing
the number of shares issued and outstanding to 2,000,000.

14.  Responsibility and Costs.  Immuno agrees to pay for all legal and other
work in connection with its  part of the proposed acquisition, the
stockholders meeting, and other corporate proceedings up through and including
the closing.  It is estimated that Immuno's expense will be approximately
$20,000 which will be paid by Immuno on or before the closing.  BHA will pay
for all of its costs in connection with the proposed acquisition.

15.  Assistance.  All parties hereto agree to take whatever reasonable steps
are required to facilitate the  consummation of the transaction contemplated
herein, including discussing the matter with members of the financial
community, stockholders and other interested parties and including the
exchange of corporate records, documents and filings.


 4

16.  Termination.  The Letter of Intent shall automatically terminate ten (10)
days after the date hereof unless accepted  by you and, after acceptance,
shall terminate on June 19, 2000, unless extended by  the written agreement of
the parties hereto. Upon termination, neither party shall have any further
obligation to the other under this agreement.

This letter sets forth  our understanding of the proposed terms of the
transaction and is not a binding agreement  on either party.  If it represents
your  understanding of the terms of our preliminary agreement,  please sign on
the below-designated line and send us a copy.

ImmunoTechnology Corporation
/S/ Mark A. Scharmann, Vice President

The undersigned, president and director of Beverly Hills Auctioneers, Inc.,
hereby agrees this Letter of Intent sets forth our preliminary agreement
regarding the matters set forth herein.

Dated: June 9, 2000

Beverly Hills Auctioneers, Inc.
/S/ Anthony Magnemi, Jr. President